| Company Address 3155 Porter Drive Palo Alto, CA 94304 United States |
PSD Comments The Company reported a net loss of $5,744,000, or $0.07 per share, for the third quarter ended September 30, 2008, compared to a net loss of $7,154,000, or $0.09 per share, for the third quarter of 2007. The decrease in net loss in 2008 compared to the same period in 2007 was primarily attributable to a decrease in external services, including costs related to manufacturing and testing of our cell products, as well as lower clinical trial costs. Total revenue for the third quarter of 2008 was $12,000, compared to $13,000 in the third quarter of 2007. Revenue for 2008 and 2007 was from licensing agreements. Cash, cash equivalents, and marketable debt securities were $21,346,000 at September 30, 2008, compared with $43,294,000 at September 30, 2007. Cash used for operating activities in the third quarter of 2008 was $4,939,000 compared to $4,903,000 in the third quarter of 2007. In October 2008, they announced preclinical results which show that their proprietary HuCNS-SC® product candidate (purified human neural stem cells) can protect the retina from progressive degeneration. Retinal degeneration leads to loss of vision in diseases such as age-related macular degeneration and retinitis pigmentosa. |
Business description StemCells, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cell-based therapeutics to treat diseases of the central nervous system and liver. The company engages in product development programs for two cell types: the human neural stem cell and human liver engrafting cells. In its central nervous system Program, the company is conducting a Phase I clinical trial to evaluate the safety and preliminary efficacy of its HuCNS-SC product candidate (purified human neural stem cells) as a treatment for infantile and late infantile neuronal ceroid lipofuscinosis; and in Liver Program, the company is in preclinical development and is continuing to improve processes to isolate and purify its human liver engrafting cells. In addition, StemCells is conducting preclinical work for spinal cord injury, myelin disorders, and retinal disorders. The company was founded in 1988 and is headquartered in Palo Alto, California. |
| Market Cap: 110.36M Shares Outstanding: 81.15M Float: 80.16M % Held by Insiders: 2.09% |
| STEM (NASDAQ) Year Founded 1988 # of Employees 63 Employees Website www.stemcellsinc.com |
| 3 Months Avg. Price: 1.15 1 Month Avg. Price: 1.23 10 Days Avg. Price: 0.980 5 Days Avg. Price: 0.950 |
| 3 Months Avg. Volume: 1.19M 1 Month Avg. Volume: 1.39M 10 Days Avg. Volume: 1.22M 5 Days Avg. Volume: 700.09K |
as of 12/8/08
as of 12/8/08
as of 12/8/08